In which country was capmatinib developed and produced?

Capmatinib (Capmatinib), trade name: Tabrecta™, is a targeted therapy drug mainly used to treat patients with MET Advanced non-small cell lung cancer (NSCLC) with exon 14 skipping mutation (METex14). The drug was discovered by Incyte Corporation, an American biopharmaceutical company, and licensed its exclusive global development and commercialization rights to Novartis, a Swiss pharmaceutical company, in 2009. Thus, the development of capmatinib originated in the United States, while its global development and commercialization are led by the Swiss company Novartis.

The trade name of capmatinib isTabrecta™. It was approved by the U.S. Food and Drug Administration in May 2020. FDA (FDA) granted accelerated approval for the treatment of adult patients with advanced non-small cell lung cancer positive for METexon14 skipping mutations. Since then, Tabrecta™ has been approved in many countries and regions, including Japan, the European Union, etc. In Japan, Tabrecta™ was approved by the Ministry of Health, Labor and Welfare (MHLW) for the treatment of METexon14 skipping mutation-positive advanced and / or recurrent unresectable non-small cell lung cancer.

The development and approval process of capmatinib reflects the importance of cross-border cooperation in global drug development. Although it was originally discovered by the American company Incyte, through cooperation with the Swiss company Novartis, capmatinib was rapidly promoted and applied globally, providing a new treatment option for patients with non-small cell lung cancer positive for METexon14 skipping mutations.

In short, the research and development of capmatinib originated in the United States, discovered by Incyte, and licensed to Novartis in Switzerland for global development and commercialization. This transnational cooperation model is of great significance in global drug development and promotes the rapid promotion and application of innovative drugs.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib